Search results
Showing 31 to 42 of 42 results for botulinum toxin type a
dose. Botulinum toxin is used second- or third-line although there is little evidence to guide dosing, which salivary...
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
Implantation of an opaque intraocular lens for intractable double vision (IPG293)
Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.
View recommendations for IPG293Show all sections
Sections for IPG293
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
residential care homes or virtual consultations when delivered by different types of health and social care practitioners, for example...
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Around 10,000 people could benefit from new migraine drug as NICE says it's cost-effective
NICE has today (12 March 2020) published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine.